Evotec
Company Snapshot
Founded: 1993
Entity Type: Public
Employees: 4,553
Region: U.S.
Revenue: $891.7 Millions
Revenue Year: 2025
Segment: Discovery & Preclinical Development
Headquarter: Hamburg, Germany
Key Geographics: U.S., Germany, France, U.K., Switzerland, Rest of the World
Corporate Address: Essener Bogen 7 22419 Hamburg, Germany Tel. +49-40-560-81-0 www.evotec.com
Company Overview
Evotec SE operates as a drug discovery alliance and development partnership firm, focusing on discovering and developing small molecule drugs across diverse therapeutic areas. The company offers various drug discovery services, including target identification and validation, sample management, hit identification, in vitro pharmacology services, integrated CMC (Chemistry, Manufacturing, and Control), and proteomics services.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Company's Business Segments
- Discovery & Preclinical Development : This segment comprises drug discovery and preclinical development services and solutions, starting with sourcing novel treatment ideas derived from patient data and continuing with target validation and lead optimization.
- Just – Evotec Biologics : This segment provides services in the areas of antibody molecular optimization, product and process design, single-use disposable, perfusion-based continuous bioprocessing platforms, covering both early-stage and commercial biomanufacturing.
Applications/End User Industries
- Non-Profit organizations
- Pharmaceuticals
- Healthcare
- Biotechnology
- Life Sciences
- Drug Discovery and Development